Intravenous Immunoglobulin Does Not Improve Clinical Outcomes Compared With Tocilizumab in Severe COVID-19
A study reveals IVIG treatment shows no significant benefits over tocilizumab for severe COVID-19, highlighting higher adverse events and costs.